-0.83% for AbbVie stock as price remains below key moving averages

Traders Union
All News
Business & Wealth
Companies
AbbVie down 0.83% today at $209.37

Highlights

ABBV trades below major moving averages, indicating persistent bearish momentum across short, medium, and long-term trends.
Momentum and trend indicators remain weak, with only a minor bounce this week and low probability of sustained upside.
Expected trading range is $205.00 to $214.00, with key support at $205.00 and further downside likely if breached.

The company stated that millions of lives are impacted worldwide by the condition. AbbVie encouraged the public to learn more about bipolar disorder and support those living with it.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

ABBV is currently trading at $209.37, which is below the MA-20 ($219.63), MA-50 ($221.73), and MA-200 ($215.72). This setup signals ongoing downward pressure in the short-, medium-, and long-term trends. The Ichimoku Kijun on D1 stands at $219.46, acting as immediate resistance for the price. Near-term support is noted at the MA-5/EMA-5 cluster ($207.56–$208.94), with key support around the MA-200 ($215.72). Immediate resistance is set by the Kijun ($219.46), while the MA-50 ($221.73) provides the next key resistance level above that.

Recent momentum signals remain weak, with the MACD on D1 in “Sell” and a negative value, supported by a low ADX (16.72), indicating lack of a strong trend. RSI (37.53) and CCI (–63.34) both point toward lingering bearishness but are not yet at extreme oversold levels, while Stoch RSI hovers in a neutral range. The BBP on D1 is in positive territory (0.51), suggesting buyer dominance for now, but this contradicts the prevailing downward bias from trend and momentum indicators. ABBV has risen $4.30 (2.09%) this week from the previous close at $205.07, now trading in the upper part of its weekly range. Weekly volatility stands at 5.72%. The tone this week reflects a recovery from the weekly low, but longer-term signals do not confirm a sustained uptrend.

For the coming week, the expected trading range is $205.00 to $214.00, which remains within 20% of the current price and aligns with typical blue-chip volatility. This range sits well off the 52-week low ($164.39) and below the 52-week high ($244.81), reflecting a neutral-to-cautious market posture. Based on W1 indicators, only one out of four signals offers a “Buy,” so the probability of a price increase is very low (less than 20%), making a further decline more likely. The baseline scenario is for ABBV to consolidate between support at $205.00 and resistance at $214.00. A bullish move would require a breakout above $214.00, targeting higher levels toward the MA clusters. A bearish scenario would see a break below $205.00, exposing ABBV to renewed selling pressure toward the next significant historical supports.

Previously it was reported that AbbVie was experiencing persistent downside pressure with analysts favoring a cautious, sideways outlook. As market conditions progress, investors should remain attentive to any decisive breakout from the current consolidation, as this could set the tone for AbbVie's next directional move.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.